/C O R R E C T I O N -- Deep Bio/
SEOUL, South Korea, Jan. 31, 2024 /PRNewswire/ -- Deep Bio, a leader in artificial intelligence (AI)-powered cancer diagnostics, proudly announced the availability of its CE-marked in-vitro diagnostic device, DeepDx Prostate, on the Swiss market.
- Deep Bio wishes to clarify that DeepDx Prostate has been placed on the Swiss market as a CE-marked in-vitro diagnostic device.
- DeepDx Prostate is an AI-powered software for the assessment of prostate cancer on digital whole slide images of hematoxylin and eosin-stained prostate core-needle biopsies.
- "We are excited to introduce DeepDx Prostate to Switzerland," said Sun Woo Kim, the CEO and founder of Deep Bio.
- Deep Bio continues to expand its global reach through partnerships with digital pathology leaders in the US, Europe, and India.